LLY

998.86

+1.07%↑

JNJ

242.72

+1%↑

ABBV

226.11

-1.67%↓

NVS

160.81

+0.66%↑

AZN

193.2

-0.6%↓

LLY

998.86

+1.07%↑

JNJ

242.72

+1%↑

ABBV

226.11

-1.67%↓

NVS

160.81

+0.66%↑

AZN

193.2

-0.6%↓

LLY

998.86

+1.07%↑

JNJ

242.72

+1%↑

ABBV

226.11

-1.67%↓

NVS

160.81

+0.66%↑

AZN

193.2

-0.6%↓

LLY

998.86

+1.07%↑

JNJ

242.72

+1%↑

ABBV

226.11

-1.67%↓

NVS

160.81

+0.66%↑

AZN

193.2

-0.6%↓

LLY

998.86

+1.07%↑

JNJ

242.72

+1%↑

ABBV

226.11

-1.67%↓

NVS

160.81

+0.66%↑

AZN

193.2

-0.6%↓

Search

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

29.81 1.39

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

28.86

Max

30.08

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-14M

-81M

Pardavimai

75K

75K

Pelnas, tenkantis vienai akcijai

-1.22

Pelno marža

-108,422.667

Darbuotojai

186

EBITDA

-7.8M

-81M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+86.54% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

377M

2B

Ankstesnė atidarymo kaina

28.42

Ankstesnė uždarymo kaina

29.81

Naujienos nuotaikos

By Acuity

50%

50%

128 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-06 19:32; UTC

Įsigijimai, susijungimai, perėmimai

Diana Shipping Increases Offer to Acquire Genco -- Update

2026-03-08 23:47; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-03-08 23:47; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Nikkei May Fall on Higher Energy Prices, Signs of U.S. Econ Weakness -- Market Talk

2026-03-08 23:46; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Falls Amid Dollar's Strength -- Market Talk

2026-03-08 23:34; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Futures Surge Above $100/bbl Amid Growing Middle East Conflict -- Market Talk

2026-03-08 23:08; UTC

Svarbiausios naujienos

Front-month WTI Crude Futures Jump 16.6%, Front-Month Brent Crude Futures Climb 15.2%

2026-03-08 23:05; UTC

Svarbiausios naujienos

Front-month Crude Oil Futures Surge Amid Rising Middle East Conflict

2026-03-08 22:37; UTC

Svarbiausios naujienos

The Long-Feared Persian Gulf Oil Squeeze Is Upon -2-

2026-03-08 22:37; UTC

Svarbiausios naujienos

The Long-Feared Persian Gulf Oil Squeeze Is Upon Us -- WSJ

2026-03-07 02:30; UTC

Svarbiausios naujienos

Iran War Is Kicking India When It's Already Down -- Barrons.com

2026-03-06 22:26; UTC

Svarbiausios naujienos

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

2026-03-06 22:07; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

2026-03-06 22:03; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-06 22:03; UTC

Rinkos pokalbiai

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

2026-03-06 21:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-06 21:37; UTC

Uždarbis

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

2026-03-06 21:25; UTC

Svarbiausios naujienos

How The Iran War Impacts Ukraine. -- Barrons.com

2026-03-06 21:17; UTC

Uždarbis

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

2026-03-06 20:50; UTC

Uždarbis

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

2026-03-06 20:46; UTC

Uždarbis

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026-03-06 20:31; UTC

Svarbiausios naujienos

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

2026-03-06 20:18; UTC

Rinkos pokalbiai

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

2026-03-06 20:12; UTC

Rinkos pokalbiai
Svarbiausios naujienos

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

2026-03-06 19:10; UTC

Rinkos pokalbiai
Svarbiausios naujienos

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

2026-03-06 18:54; UTC

Rinkos pokalbiai

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

2026-03-06 18:44; UTC

Rinkos pokalbiai
Svarbiausios naujienos

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

2026-03-06 18:08; UTC

Uždarbis

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026-03-06 18:04; UTC

Uždarbis

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

2026-03-06 18:04; UTC

Uždarbis

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

2026-03-06 17:49; UTC

Rinkos pokalbiai

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

86.54% į viršų

12 mėnesių prognozė

Vidutinis 54.9 USD  86.54%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

9

Pirkti

1

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

128 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat